BB Biotech

From Wikipedia, the free encyclopedia
Jump to: navigation, search
BB Biotech AG
Type Aktiengesellschaft
Traded as SIXBION, FWBBBZA
Industry Investments
Founded Schaffhausen, Switzerland (9 November 1993 (9 November 1993))
Headquarters Küsnacht, Switzerland
Key people Erich Hunzker (Chairman)
Products Investment in biotechnology companies
Operating income CHF 391 million (2012)[1]
Profit Increase (CHF 367.8 million) (2012)[2]
Total assets CHF 1.3763 billion (2012)[1]
Total equity CHF 1.234 billion (2012)[1]
Website www.bbbiotech.ch

BB Biotech AG is a Swiss investment company in the field of biotechnology. Since 1993 it is listed on the SIX Swiss Exchange, since 1997 on the German TecDAX and since 2000 on the Italian Borsa Italiana.[3]

At of September 30, 2013the six largest holdings in the BB Biotech portfolio were (in order of value): a 13% stake in Celgene; 11% of Isis Pharmaceuticals; 10.4% of Actelion; 9.6% of Gilead; 7.7% of Incyte and 4.5% of Vertex.

References[edit]

  1. ^ a b c "Annual Report 2012" (PDF). BB Biotech. Retrieved 29 November 2013. 
  2. ^ "Annual Report 2010" (PDF). BB Biotech. Retrieved 13 March 2011. 
  3. ^ "BB Biotech - Facts & Figures". BB Biotech. Retrieved 2013-11-28. 

External links[edit]